Tagrisso osimertinib: Phase III data

The open-label, international Phase III AURA3 trial in 419 patients with EGFR T790M mutation-positive, locally

Read the full 152 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE